|PRINT | CLOSE WINDOW|
Sen. Charles Schumer has been told there will be no more layoffs at Bausch & Lomb Inc., no further cuts to research and development and manufacturing, and as many as 50 research jobs will be transferred to Rochester from California, he said Thursday.
Schumer, D-N.Y., announced the commitments in a statement following a phone conversation with Valeant Pharmaceuticals International Inc. CEO Michael Pearson.
Valeant announced its $8.7 billion acquisition of Bausch & Lomb on May 27. The deal was consummated Aug. 6, with Valeant announcing 400 jobs cuts by November.
All existing vision care R&D will continue to be done in Rochester, Schumer said. In addition, 25 to 50 research jobs for the surgical intraocular lens business will be transferred here.
Valeant also will reconsider its plan to manufacturer its silicon hydrogel monthly contact lenses in Ireland rather than Rochester, Schumer said. That lens, commonly referred to as Zeus, was researched and developed in Rochester and its pilot manufacturing line is here.
(c) 2013 Rochester Business Journal. To obtain permission to reprint this article, call 585-546-8303 or email firstname.lastname@example.org.